643 related articles for article (PubMed ID: 15733030)
1. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
[TBL] [Abstract][Full Text] [Related]
2. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
[TBL] [Abstract][Full Text] [Related]
3. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature.
Andrus MR
Pharmacotherapy; 2004 Feb; 24(2):285-90. PubMed ID: 14998226
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
Bakhai A; Rigney U; Hollis S; Emmas C
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927
[TBL] [Abstract][Full Text] [Related]
5. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
[TBL] [Abstract][Full Text] [Related]
6. [Drug combinations: statins and niacin].
Borges JL
Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():36-41. PubMed ID: 16400397
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
[TBL] [Abstract][Full Text] [Related]
9. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Saw J; Steinhubl SR; Berger PB; Kereiakes DJ; Serebruany VL; Brennan D; Topol EJ;
Circulation; 2003 Aug; 108(8):921-4. PubMed ID: 12925453
[TBL] [Abstract][Full Text] [Related]
10. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
Saw J; Brennan DM; Steinhubl SR; Bhatt DL; Mak KH; Fox K; Topol EJ;
J Am Coll Cardiol; 2007 Jul; 50(4):291-5. PubMed ID: 17659194
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
12. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
Molden E; Skovlund E; Braathen P
Drug Saf; 2008; 31(7):587-96. PubMed ID: 18558792
[TBL] [Abstract][Full Text] [Related]
13. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Hoffman KB; Kraus C; Dimbil M; Golomb BA
PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
[TBL] [Abstract][Full Text] [Related]
14. The potential for drug interactions with statin therapy in Ireland.
Heerey A; Barry M; Ryan M; Kelly A
Ir J Med Sci; 2000; 169(3):176-9. PubMed ID: 11272871
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Lemahieu WP; Hermann M; Asberg A; Verbeke K; Holdaas H; Vanrenterghem Y; Maes BD
Am J Transplant; 2005 Sep; 5(9):2236-43. PubMed ID: 16095503
[TBL] [Abstract][Full Text] [Related]
16. The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
S Afr Med J; 2002 Aug; 92(8):596-7. PubMed ID: 12244613
[No Abstract] [Full Text] [Related]
17. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
18. [Prevalence of potential drug-drug interactions in ambulatory patients with statin therapy].
Rätz Bravo AE; Tchambaz L; Krähenbuhl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
Praxis (Bern 1994); 2006 Feb; 95(5):139-46. PubMed ID: 16509450
[TBL] [Abstract][Full Text] [Related]
19. [Interaction risk with statin switch].
Molden E; Westergren T
Tidsskr Nor Laegeforen; 2007 Feb; 127(4):428-31. PubMed ID: 17304269
[TBL] [Abstract][Full Text] [Related]
20. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.
Devold HM; Molden E; Skurtveit S; Furu K
Br J Clin Pharmacol; 2009 Feb; 67(2):234-41. PubMed ID: 19220274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
